The vast majority of pancreatic ductal adenocarcinomas (PDAC) involve activating mutations in KRAS (KRAS*) and as with other KRAS* cancers, PDAC show minimal response to existing therapies used in the clinic. While no satisfactory KRAS*-speclfic drugs are currently available, inhibitors of MEK and PI3K (MEKi and PI3Ki)?pathways necessary for KRAS*-mediated cellular transformation in vitro, are now being introduced into clinical trials. The central hypothesis guiding this project is that PDAC utilize the PI3K and MEK pathways In a redundant way to drive tumor growth and that a critical role for these pathways Involves the regulation of tumor metabolism. The overall goals of this proposal are to determine the impact of MEKi/PI3Ki on PDAC cell signaling, metabolism, and therapeutic response. These efforts will be coupled with an investigation of metabolic biomarkers for MEK/PI3K signaling and identification of mechanisms of therapeutic resistance which would be critical in future therapeutic trials.
The Aims are: 1. Determine the impact of MEK/PI3K inhibition in PDAC. Genetically engineered mouse models as well as genomically characterized organotypic human PDAC cultures will be used to compare the cellular responses and signaling pathway alterations provoked by genetic or pharmacologic MEKi/PI3Ki against the backdrop of different combinations of tumor suppressor mutations found in human PDAC. 2. Determine the impact of MEK/PISK inhibition on PDAC metabolism. Glutamine and glucose are the main nutrients used by tumor cells for energy generation and for anabolic processes. The contribution of these nutrients to PDAC metabolism in vivo and the impact of MEKi/PI3Ki on their utilization will be determined using a series of radioisotope labeling, molecular imaging, and LC-MS approaches. These studies will give insight Into the regulation of PDAC metabolism and define biomarkers for the activity of these pathways. 3. Determine the mechanisms of resistance to MEKi/PI3Ki in PDAC. Preliminary studies indicate that mouse PDAC models will eventually develop acquired resistance to MEKi/PI3Ki. The mechanisms of acquired resistance will be explored by a series of phosphoproteomics and genetic analyses. In addition, as a means to increase the bi

Public Health Relevance

Pancreatic ductal adenocarcinoma (PDAC) is the 4th most common cause of cancer-related death in the USA, carrying an average survival of only 6 months. Our proposed studies will test the importance of two interrelated biochemical signaling pathways in PDAC growth, develop imaging methods to monitor whether drugs against these pathways are effective, and determine how PDAC become resistant to these drugs. The

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA117969-09
Application #
8603766
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
9
Fiscal Year
2014
Total Cost
$392,565
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Lundquist, Mark R; Goncalves, Marcus D; Loughran, Ryan M et al. (2018) Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy. Mol Cell 70:531-544.e9
Hopkins, Benjamin D; Pauli, Chantal; Du, Xing et al. (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499-503
Biancur, Douglas E; Kimmelman, Alec C (2018) The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. Biochim Biophys Acta Rev Cancer 1870:67-75
Chen, Yang; LeBleu, Valerie S; Carstens, Julienne L et al. (2018) Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent metastasis program. EMBO Mol Med 10:
Hill, Margaret A; Alexander, William B; Guo, Bing et al. (2018) Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 78:4445-4451
Mendt, Mayela; Kamerkar, Sushrut; Sugimoto, Hikaru et al. (2018) Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3:
Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822
Anglin, Justin; Zavareh, Reza Beheshti; Sander, Philipp N et al. (2018) Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Bioorg Med Chem Lett 28:2675-2678
Yang, Annan; Herter-Sprie, Grit; Zhang, Haikuo et al. (2018) Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. Cancer Discov 8:276-287
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945

Showing the most recent 10 out of 134 publications